Babesiosis cases across metropolitan France
Official title: Human Babesiosis in Metropolitan France: a Retrospective and Multicenter Descriptive Analysis.
Run by University Hospital, Strasbourg, France · NCT07345988 · Data updated 2026-11-12
This project will collect and review data to see how babesiosis affects adults diagnosed and treated in French hospitals between 2000 and 2024.
Quick facts
| Study type | Observational |
|---|---|
| Ages | 18 Years and up |
| Sex | All |
| Enrollment | 100 (estimated) |
| Sponsor | University Hospital, Strasbourg, France Academic / other |
| Locations | 1 site (Strasbourg) |
| Status | Recruiting |
| Started | November 4, 2025 |
| Main results expected | May 2027 |
| Study ends | May 4, 2027 |
| Registry record updated | January 16, 2026 |
| Trial ID | NCT07345988 on ClinicalTrials.gov |
Is this trial a fit for you?
✓Likely a good fit
Adults aged 18 or older with babesiosis confirmed by blood smear or PCR who were treated at participating French centers between January 1, 2000 and December 31, 2024 and who did not refuse participation.
✕Probably not a fit
People without laboratory-confirmed babesiosis, children, or those treated outside the participating centers are unlikely to receive direct benefit from this dataset.
A plain-English reading of the study's rules. Only the study team can confirm whether you qualify.
What this trial studies
This is a retrospective observational review of adult patients (≥18 years) with babesiosis confirmed by blood smear or PCR who were treated at CHU Strasbourg and associated centers from January 1, 2000 to December 31, 2024. Investigators will extract clinical, laboratory, treatment, and outcome data to describe epidemiology, presentation, severity, and risk factors such as splenectomy, immunosuppression, and advanced age. The effort addresses underdiagnosis and limited case numbers by aggregating cases to clarify typical and severe clinical courses. Findings aim to inform clinicians and public-health planning for tick-borne babesiosis in metropolitan France.
Why it matters
Potential benefit: If successful, the project could help clinicians recognize and manage babesiosis earlier and guide public-health measures to reduce severe outcomes in high-risk patients.
How similar studies have gone: Small case series and regional reports exist, but comprehensive national or multicenter datasets for human babesiosis in France remain limited.
Who can join: the full rules
Show full inclusion / exclusion criteria
Inclusion Criteria: * Adult subjects (≥18 years old) * With a diagnosis of babesiosis confirmed by blood smear or PCR * Treated in associated centers during the period from January 1, 2000, to December 31, 2024 Exclusion Criteria: \- Refusal to participate in the study
Where it's running
-
Centre de référence des maladies vectorielles à tiques, CNR Borrelia - CHU de Strasbourg - France
Strasbourg, France Recruiting
Study contacts
- Study coordinator: Victor GERBER, MD
- Email: victor.gerber@chru-strasbourg.fr
- Phone: 33 3 68 85 37 97
Similar studies
Other studies for the same condition or treatment. Recruiting studies are listed first.
-
Tick-borne infections in Finland: a broad, multicenter look at Lyme, TBE and other infections
This study tests how common and how these infections show up in people with suspected tick-borne disease in Finland.
-
Comparing Tafenoquine with Placebo for Treating Babesiosis
This study is testing if a new medication called Tafenoquine can help hospitalized patients with babesiosis get better compared to a placebo.
-
Tafenoquine treatment for chronic babesiosis with severe fatigue
This open-label Phase 2 trial tests tafenoquine 100 mg to see if it reduces severe fatigue and other symptoms in adults with chronic babesiosis who have laboratory evidence of recent Babesia exposure.
How to take part
- Review the eligibility criteria above with your treating physician.
- Check the official listing on ClinicalTrials.gov for the latest contact details and recruitment status.
- Contact the study coordinator or principal investigator to ask for pre-screening. Pre-screening is free and never obligates you to enroll.